Disc Medicine Advances Pipeline with Key Data Readouts and FDA Alignment
Event summary
- Disc Medicine completed a Type A meeting with the FDA, aligning that successful Phase 3 APOLLO study data could support a CRL response for bitopertin, with topline results expected in Q4 2026.
- Launched an Expanded Access Program (EAP) for bitopertin, providing eligible EPP patients early access to treatment.
- Presented positive clinical data updates from the RALLY-MF Phase 2 trial of selcodebart in anemia of myelofibrosis and the HELIOS open-label extension trial of bitopertin in EPP.
- Completed enrollment for the RESTORE-PV Phase 2 study of DISC-3405 in polycythemia vera, with initial data expected in Q3 2026.
The big picture
Disc Medicine is positioning itself for multiple pivotal milestones in its hematology-focused pipeline, with strategic alignment from the FDA on bitopertin's regulatory path. The company's strong financial position provides a runway into 2029, but execution risk remains high as it prepares for key data readouts across its portfolio. Success in these trials could significantly enhance its valuation and competitive standing in the hematologic diseases space.
What we're watching
- Regulatory Pathway
- Whether the Phase 3 APOLLO study results will meet FDA expectations and support a traditional approval for bitopertin.
- Pipeline Momentum
- The pace at which Disc Medicine can advance selcodebart and DISC-3405 into pivotal-stage development in 2027.
- Financial Runway
- How Disc Medicine will manage its cash position to support operational plans into 2029 amid increasing R&D expenses.